{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:49:07Z","timestamp":1788918547847,"version":"build-2803163510"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A single 5-mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years. This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy.<\/jats:p><jats:p>Introduction: Zoledronic acid (ZOL) is a potent bisphosphonate that produces a rapid and complete control of the increased bone turnover of Paget's disease. Long-term control of disease activity is an important aim of treatment in the hope that this will reduce the risk of complications such as deformity, fracture, and degenerative joint disease.<\/jats:p><jats:p>Materials and Methods: This study compares the ability of ZOL 5 mg given as a 15-minute intravenous infusion with risedronate (RIS) 30 mg daily by mouth for 60 days to maintain long-term control of bone turnover. No bisphosphonate was given during the extension study. All patients (n = 296) who achieved a therapeutic response, defined as normalization or a &amp;gt;75% reduction in the total alkaline phosphatase (total ALP) excess above the midpoint of the reference range, were eligible for inclusion.<\/jats:p><jats:p>Results: ZOL maintained the mean level of total ALP at the middle of the reference range, whereas those treated with risedronate showed a linear increase in total ALP from the 6-month post-treatment time-point. Both treatments resulted in a linear relationship between the 6-month nadir and 24-month total ALP. The relationship for RIS was shifted upward, showing that for a given level of post-treatment biochemical activity, bone turnover increased with time. This was in contrast to the ZOL-treated patients where total ALP generally remained unchanged over this 18-month extension period. A similar pattern of response was seen with the other bone turnover markers.<\/jats:p><jats:p>Conclusions: ZOL maintains bone turnover within the reference range over 24 months from the initiation of treatment. A reduction in the incidence and severity of long-term complications may require persistent normalization of bone turnover over many years, and this now seems a realistic possibility with ZOL.<\/jats:p>","DOI":"10.1359\/jbmr.061001","type":"journal-article","created":{"date-parts":[[2006,10,10]],"date-time":"2006-10-10T13:43:11Z","timestamp":1160487791000},"page":"142-148","source":"Crossref","is-referenced-by-count":123,"title":["Long-Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate"],"prefix":"10.1093","volume":"22","author":[{"given":"David","family":"Hosking","sequence":"first","affiliation":[{"name":"City Hospital, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Lyles","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, VA Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques P","family":"Brown","sequence":"additional","affiliation":[{"name":"Le Centre Hospitalier Universitaire de Quebec, Sainte-Foy, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D","family":"Fraser","sequence":"additional","affiliation":[{"name":"Royal Liverpool University Hospital, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Miller","sequence":"additional","affiliation":[{"name":"Colorado Center for Bone Research, Lakewood, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Diaz","family":"Curiel","sequence":"additional","affiliation":[{"name":"Fundacion Jimenez Diaz. Universidad Autonoma, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Devogelaer","sequence":"additional","affiliation":[{"name":"Universite Catholique de Louvain, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hooper","sequence":"additional","affiliation":[{"name":"The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqin","family":"Su","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Zelenakas","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Pak","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiwo","family":"Fashola","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Saidi","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Fink","family":"Eriksen","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R","family":"Reid","sequence":"additional","affiliation":[{"name":"University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020319215656500_bib1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1359\/jbmr.2001.16.8.1379","article-title":"A clinical approach to diagnosis and management of Paget's disease of bone","volume":"16","author":"Lyles","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024020319215656500_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S8756-3282(02)00817-7","article-title":"Guidelines on the management of Paget's disease of bone","volume":"31","author":"Selby","year":"2002","journal-title":"Bone"},{"key":"2024020319215656500_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"2024020319215656500_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ddr.10071","article-title":"Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption","volume":"55","author":"Green","year":"2002","journal-title":"Drug Dev Res"},{"key":"2024020319215656500_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"2024020319215656500_bib6","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"A single infusion of zoledronic acid improves remission rates in Paget's disease: A randomized controlled comparison with risedronate","volume":"353","author":"Reid","year":"2005","journal-title":"N Engl J Med"},{"key":"2024020319215656500_bib7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.2002.17.3.465","article-title":"Incidence and natural history of Paget's disease of bone in England and Wales","volume":"17","author":"Van Staa","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024020319215656500_bib8","first-page":"755","article-title":"Duration of effect of oral diphosphonate therapy in Paget's disease of bone","volume":"64","author":"Gray","year":"1987","journal-title":"Q J Med"},{"key":"2024020319215656500_bib9","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/jbmr.5650081209","article-title":"Determinants of remission of Paget's disease of bone","volume":"8","author":"Patel","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020319215656500_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/1529-0131(199802)41:2<354::AID-ART20>3.0.CO;2-5","article-title":"Measurement of urinary excretion of nonisomerized and beta isomerized forms of type 1 collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease","volume":"41","author":"Garnero","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2024020319215656500_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.295.6609.1301","article-title":"Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD)","volume":"295","author":"Harinck","year":"1987","journal-title":"BMJ"},{"key":"2024020319215656500_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jbmr.5650080208","article-title":"Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate","volume":"8","author":"Schweitzer","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020319215656500_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/8756-3282(95)00437-8","article-title":"Duration of response with oral clodronate in Paget's disease of bone","volume":"18","author":"Khan","year":"1996","journal-title":"Bone"},{"key":"2024020319215656500_bib14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bone.2003.03.001","article-title":"Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy","volume":"33","author":"Eekhoff","year":"2003","journal-title":"Bone"},{"key":"2024020319215656500_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jbmr.5650070308","article-title":"Bisphosphonate space measurement in Paget's disease of bone treated with APD","volume":"7","author":"Stone","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024020319215656500_bib16","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1359\/jbmr.2003.18.5.868","article-title":"Relation between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (Olpadronate) in patients with Paget's disease of bone","volume":"18","author":"Cremers","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020319215656500_bib17","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","article-title":"Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study","volume":"13","author":"Siris","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020319215656500_bib18","first-page":"961","article-title":"Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone","volume":"81","author":"Siris","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319215656500_bib19","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/rheumatology\/keh185","article-title":"Long term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment","volume":"43","author":"Alvarez","year":"2004","journal-title":"Rheumatol"},{"key":"2024020319215656500_bib20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bone.2004.03.023","article-title":"Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone","volume":"35","author":"Reid","year":"2004","journal-title":"Bone"},{"key":"2024020319215656500_bib21","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/clinchem\/41.11.1592","article-title":"Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease","volume":"41","author":"Blumsohn","year":"1995","journal-title":"Clin Chem"},{"key":"2024020319215656500_bib22","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1359\/JBMR.041212","article-title":"Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone","volume":"20","author":"Alexandersen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020319215656500_bib23","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJM197312272892601","article-title":"Influence of disodium etidronate on clinical and laboratory manifestations of Pagets disease of bone (osteitis deformans)","volume":"289","author":"Altman","year":"1973","journal-title":"N Engl J Med"},{"key":"2024020319215656500_bib24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bone.2003.12.011","article-title":"A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone","volume":"34","author":"Walsh","year":"2004","journal-title":"Bone"},{"key":"2024020319215656500_bib25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"2024020319215656500_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5694\/j.1326-5377.2005.tb06761.x","article-title":"Bisphosphonates and avascular necrosis of the jaw: A possible association","volume":"182","author":"Carter","year":"2005","journal-title":"Med J Aust"},{"key":"2024020319215656500_bib27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: Bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.061001","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/22\/1\/142\/56550282\/5650220117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/22\/1\/142\/56550282\/5650220117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T10:08:35Z","timestamp":1736590115000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/22\/1\/142-148\/7597118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.061001","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,1,1]]},"published":{"date-parts":[[2007,1,1]]}}}